HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fitzgerald, P. M. Articles by Darke, P. L. Search for Related Content PubMed PubMed Citation Articles by Fitzgerald, P. M. Articles by Darke, P. L. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 265, Issue 24, 14209-14219, Aug, 1990

Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution

PM Fitzgerald, BM McKeever, JF VanMiddlesworth, JP Springer, JC Heimbach, CT Leu, WK Herber, RA Dixon and PL Darke
Department of Biophysical Chemistry, Merck Sharp and Dohme Research Laboratories, Rahway, New Jersey 07065.

The mode of binding of acetyl-pepstatin to the protease from the human immunodeficiency virus type 1 (HIV-1) has been determined by x-ray diffraction analysis. Crystals of an acetyl-pepstatin-HIV-1 protease complex were obtained in space group P2(1)2(1)2 (unit cell dimensions a = 58.39 A, b = 86.70 A, c = 46.27 A) by precipitation with sodium chloride. The structure was phased by molecular replacement methods, and a model for the structure was refined using diffraction data to 2.0 A resolution (R = 0.176 for 12901 reflections with I greater than sigma (I); deviation of bond distances from ideal values = 0.018 A; 172 solvent molecules included). The structure of the protein in the complex has been compared with the structure of the enzyme without the ligand. A core of 44 amino acids in each monomer, including residues in the active site and residues at the dimer interface, remains unchanged on binding of the inhibitor (root mean square deviation of alpha carbon positions = 0.39 A). The remaining 55 residues in each monomer undergo substantial rearrangement, with the most dramatic changes occurring at residues 44-57 (these residues comprise the so-called flaps of the enzyme). The flaps interact with one another and with the inhibitor so as to largely preserve the 2-fold symmetry of the protein. The inhibitor is bound in two approximately symmetric orientations. In both orientations the peptidyl backbone of the inhibitor is extended; a network of hydrogen bonds is formed between the inhibitor and the main body of the protein as well as between the inhibitor and the flaps. Hydrophobic side chains of residues in the body of the protein form partial binding sites for the side chains of the inhibitor; hydrophobic side chains of residues in the flaps complete these binding sites.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. N. L. Nalam, A. Peeters, T. H. M. Jonckers, I. Dierynck, and C. A. Schiffer Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease J. Virol., September 1, 2007; 81(17): 9512 - 9518. [Abstract] [Full Text] [PDF]

				B. C. Logsdon, J. F. Vickrey, P. Martin, G. Proteasa, J. I. Koepke, S. R. Terlecky, Z. Wawrzak, M. A. Winters, T. C. Merigan, and L. C. Kovari Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity J. Virol., March 15, 2004; 78(6): 3123 - 3132. [Abstract] [Full Text] [PDF]

				M. B. Rao, A. M. Tanksale, M. S. Ghatge, and V. V. Deshpande Molecular and Biotechnological Aspects of Microbial Proteases Microbiol. Mol. Biol. Rev., September 1, 1998; 62(3): 597 - 635. [Abstract] [Full Text] [PDF]

				T. W. Ridky, D. Bizub-Bender, C. E. Cameron, I. T. Weber, A. Wlodawer, T. Copeland, A. M. Skalka, and J. Leis Programming the Rous Sarcoma Virus Protease to Cleave New Substrate Sequences J. Biol. Chem., May 3, 1996; 271(18): 10538 - 10544. [Abstract] [Full Text] [PDF]

				P. Lam, P. Jadhav, C. Eyermann, C. Hodge, Y Ru, L. Bacheler, J. Meek, M. Otto, M. Rayner, Y. Wong, et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors Science, January 21, 1994; 263(5145): 380 - 384. [Abstract] [PDF]

				I. D. Kuntz Structure-Based Strategies for Drug Design and Discovery Science, August 21, 1992; 257(5073): 1078 - 1082. [Abstract] [PDF]

				M Schnolzer and S. Kent Constructing proteins by dovetailing unprotected synthetic peptides: backbone-engineered HIV protease Science, April 10, 1992; 256(5054): 221 - 225. [Abstract] [PDF]